Cell And Gene Therapy Contract Development And Manufacturing Organization - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

Cell therapy commanded 69.98% of the cell and gene therapy contract development and manufacturing organization market in 2025, buoyed by six commercial CAR-T products and an expanding allogeneic pipeline. Stem-cell platforms account for the largest share in cell therapy, favoured for established expansion, cryopreservation, and QC workflows. Engineered cell approaches such as CAR-NK and Yδ T cells are gaining speed as improved gene-editing tools shorten development cycles. Despite its smaller base, gene therapy is projected to register a 16.85% CAGR through 2031, closing the gap swiftly.

According to Mordor Intelligence, the cell and gene therapy contract development and manufacturing organization market size is valued at USD 3.71 billion in 2025. This report is Segmented by Product (Cell Therapy {Stem-Cell-Based, and More} Gene Therapy {Viral Vectors, Non-Viral Vectors}), Stage (Pre-Clinical, Clinical, Commercial), Service Type (Process Development, GMP Manufacturing, and More), and Geography (North America, Europe, Asia Pacific, More). The Market Forecasts are Provided in Terms of Value (USD).

Global Cell And Gene Therapy Contract Development And Manufacturing Organization Market Trends and Insights

Rise in CGT Clinical Pipeline

Over 2,000 active programs are in development, a figure that dwarfs the capacity commissioned before 2024. The US FDA created the Office of Therapeutic Products to streamline reviews and anticipates double-digit approvals each year through 2025. Each candidate demands bespoke viral-vector or cell-expansion workflows, expertise that most sponsors lack internally. Commercial approvals such as Casgevy, Lyfgenia, and prademagene zamikeracel validate demand and trigger multi-batch clinical supply orders. North America and Europe host 80% of trials, straining local facilities and allowing premium pricing. The driver, therefore, underpins sustained double-digit growth for the cell and gene therapy contract development and manufacturing organization market.

Rising Prevalence of Genetic Diseases & Cancer

Roughly 400 million patients live with a genetic disorder, and global cancer incidence is increasing 2-3% a year.Precision-medicine advances have unlocked previously untreatable targets using vector-based approaches. CAR-T therapies now command list prices of USD 400,000-500,000 and demonstrate the willingness of payers to reimburse one-time interventions. Ageing demographics in high-income regions swell the eligible population, while contingency approvals for diabetes and cardiovascular gene therapies hint at mainstream uptake. CDMOs well-positioned to supply larger batch sizes will benefit most as the indication size widens.

Limited High-Throughput Analytics for Large-Scale AAV Production

Complete AAV lot release now demands up to four weeks, largely due to capsid-ratio assays and genome integrity tests. Slow analytical turnaround restricts campaign throughput and inflates inventory costs. Equipment vendors are launching automation modules, but regulatory validation prolongs adoption. The bottleneck is pronounced in US and European plants, where compliance expectations remain highest. CDMOs investing in inline analytics and machine-learning-driven release will achieve competitive differentiation.

Other drivers and restraints analyzed in the detailed report include:

1. VC & Big-Pharma Funding Surge
2. Outsourcing Preference of Small CGT Developers
3. Complex, Manual-Intensive Manufacturing & Regulatory Hurdles

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Viral vectors-particularly AAV-retain pricing power given their safety and tissue-tropism advantages. The first FDA-cleared European-manufactured batch of Iovance's AMTAGVI in 2024 underscored commercial viability and opened cross-border supply lines. Non-viral modalities, notably lipid nanoparticles and minicircle DNA, are drawing capital because they can circumvent immunogenicity and scaling issues inherent to viral systems.

Batch sizes for allogeneic cell therapies are forecast to rise fivefold, driving demand for 2,000 L closed bioreactors and automated sterile welding systems. Gene therapy manufacturing, once restricted to 200 L batches, is rapidly migrating to 1,000 L-2,000 L single-use fermenters, compressing the cost per dose. Synergies exist: CDMOs with dual-capability suites can cross-utilize upstream operations, raising asset utilization rates and cushioning the impact of any one modality cycle.

Complete Report Scope:

• By Product
  • Cell Therapy
    • Stem-cell-based
    • Non-stem-cell-based
    • Other cell therapies
  • Gene Therapy
    • Viral Vectors
    • Non-viral Vectors
• By Stage
  • Pre-clinical
  • Clinical
  • Commercial
• By Service Type
  • Process Development
  • GMP Manufacturing
  • Analytical Testing / QC
  • Fill-Finish & Packaging
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 43.75% of global revenue in 2025, supported by the FDA's clear pathways, a dense cluster of start-ups, and an investor base willing to underwrite early clinical studies. The United States alone hosted more than 60% of active trials, compelling CDMOs such as Thermo Fisher to commit USD 475 million for a Princeton expansion and Samsung Biologics to allocate capacity through strategic partnerships. However, the region's cost base and a tightening labour pool inflate delivery times. CDMOs respond by raising process-development fees and offering workforce-training partnerships with community colleges to stabilize recruitment.

Asia Pacific is projected to deliver the fastest 16.12% CAGR through 2031, challenging historic dominance. China's National Development and Reform Commission funded multiple industrial parks, with WuXi Biologics adding capacities in Singapore and the United States while simultaneously expanding its Wuxi campus. Japan's Pharmaceuticals and Medical Devices Agency created a Fast Track similar to the US Breakthrough Therapy tag, cutting median review times by four months. South Korea's Lotte Biologics has earmarked USD 3.3 billion for a 400,000 L plant in Incheon, signalling intent to anchor regional demand. Cost-competitive labour and modern infrastructure give the region pricing leverage that lures Western innovators into joint ventures.

Europe maintains a mature but slower-growth profile. EMA's centralised authorisation system offers predictability, yet divergent national GMP inspections and higher energy costs temper agility. Lonza's Visp campus and AGC Biologics' Heidelberg facility continue to draw projects that value track record over price. Cross-border supply chains connect European batch release to Middle Eastern clinical sites, illustrating the region's role as a regulatory fulcrum. Meanwhile, pockets of greenfield investment appear in Ireland and Portugal, driven by grants and skilled talent availability.

1. Lonza Group
2. Catalent
3. Thermo Fisher Scientific (Patheon)
4. WuXi Advanced Therapies
5. Samsung Group
6. AGC Biologics
7. Charles River Labs (Cognate)
8. Recipharm
9. FUJIFILM
10. Minaris Regenerative Medicine
11. PCI Pharma Services
12. Almac Group
13. Pfizer CentreOne
14. KBI Biopharma
15. BioCentriq
16. ElevateBio
17. Yposkesi
18. Genezen
19. 3P Biopharmaceuticals
20. Oxford Biomedica

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support